|
covid-19 |
37 |
|
influenza |
31 |
|
sars-cov-2 |
23 |
|
surveillance |
19 |
|
humans |
18 |
|
hong kong |
17 |
|
medical sciences |
17 |
|
vaccination |
15 |
|
transmission dynamics |
14 |
|
china |
13 |
|
hong kong - epidemiology |
13 |
|
transmissibility |
13 |
|
adult |
12 |
|
disease outbreaks |
12 |
|
emergency department |
12 |
|
epidemiology |
12 |
|
meta-analysis |
11 |
|
2019 novel coronavirus disease |
10 |
|
child |
10 |
|
disease burden |
10 |
|
disparities |
10 |
|
intervention |
10 |
|
prediction |
10 |
|
socioeconomic |
10 |
|
work from home |
10 |
|
acute lung injury |
9 |
|
alveolar fluid clearance |
9 |
|
avian |
9 |
|
avian influenza |
9 |
|
hav |
9 |
|
hbv |
9 |
|
hcv |
9 |
|
hev |
9 |
|
immigration |
9 |
|
mass testing |
9 |
|
mesenchymal stromal cells |
9 |
|
older adults |
9 |
|
reproduction number |
9 |
|
temperature |
9 |
|
age distribution |
8 |
|
aged |
8 |
|
death |
8 |
|
disease surveillance |
8 |
|
gastroenterology |
8 |
|
human influenza |
8 |
|
influenza-like illness |
8 |
|
middle aged |
8 |
|
molecular epidemiology |
8 |
|
seasons |
8 |
|
systematic review |
8 |
|
transmission |
8 |
|
basic reproduction number |
7 |
|
chicken |
7 |
|
china - epidemiology |
7 |
|
communicable disease control - methods |
7 |
|
communicable diseases, emerging - prevention and control - transmission |
7 |
|
coronavirus disease |
7 |
|
face masks |
7 |
|
forecasting |
7 |
|
hospitalization |
7 |
|
importation |
7 |
|
influenza a virus |
7 |
|
influenza a virus, h7n9 subtype |
7 |
|
influenza in birds - prevention and control - transmission |
7 |
|
influenza, human - prevention and control - transmission |
7 |
|
severe acute respiratory syndrome |
7 |
|
severity |
7 |
|
united kingdom |
7 |
|
variant |
7 |
|
animals |
6 |
|
attitudes |
6 |
|
avian influenza a (h7n9) |
6 |
|
case clusters |
6 |
|
child, preschool |
6 |
|
children |
6 |
|
clinical diagnosis |
6 |
|
clinical prediction rule |
6 |
|
coronavirus disease 2019 |
6 |
|
corticosteroids |
6 |
|
disease transmission |
6 |
|
dose fractionation |
6 |
|
enterovirus |
6 |
|
epidemiologic methods |
6 |
|
epidemiological monitoring |
6 |
|
feces - virology |
6 |
|
generation time |
6 |
|
h7n9 subtype |
6 |
|
high-rise buildings |
6 |
|
hospital emergency setting |
6 |
|
humidity |
6 |
|
incubation period |
6 |
|
infectious disease outbreak |
6 |
|
influenza a |
6 |
|
influenza a virus, h1n1 subtype |
6 |
|
influenza a virus, h9n2 subtype - isolation & purification |
6 |
|
influenza in birds - mortality - transmission |
6 |
|
influenza virus |
6 |
|
influenza, human - epidemiology - prevention & control - transmission |
6 |
|
influenza, human - mortality |
6 |
|
knowledge |
6 |
|
line list |
6 |
|
meticillin-resistant staphylococcus aureus |
6 |
|
models, biological |
6 |
|
nosocomial transmission |
6 |
|
pandemic |
6 |
|
population surveillance - methods |
6 |
|
poultry - virology |
6 |
|
respiration, artificial - statistics and numerical data |
6 |
|
review |
6 |
|
schools |
6 |
|
seasonality |
6 |
|
seriousness |
6 |
|
seroprevalence |
6 |
|
spa type |
6 |
|
suicide |
6 |
|
weather |
6 |
|
a(h7n9) |
5 |
|
absenteeism |
5 |
|
adolescent |
5 |
|
aged, 80 and over |
5 |
|
airborne particles |
5 |
|
antibiotics |
5 |
|
antivirals |
5 |
|
betacoronavirus |
5 |
|
chinese medicine;multi-centre |
5 |
|
communicable diseases |
5 |
|
community-acquired infections |
5 |
|
control |
5 |
|
controlled study |
5 |
|
coronavirus infection |
5 |
|
credible interval |
5 |
|
cross infection - microbiology - prevention and control - transmission |
5 |
|
dashboard |
5 |
|
disease activity |
5 |
|
disease control |
5 |
|
disease severity |
5 |
|
dispersion parameter |
5 |
|
dissemination |
5 |
|
environmental surveillance |
5 |
|
flu like syndrome |
5 |
|
handwashing - methods |
5 |
|
human density |
5 |
|
influenza a virus - physiology |
5 |
|
influenza and respiratory viruses |
5 |
|
influenza b virus - physiology |
5 |
|
influenza virus a h9n2 |
5 |
|
influenza, human - pathology - virology |
5 |
|
interferons |
5 |
|
isolation delays |
5 |
|
live poultry trader |
5 |
|
methicillin-resistant staphylococcus aureus - isolation and purification |
5 |
|
omicron |
5 |
|
patient isolation - methods |
5 |
|
population-based cohort |
5 |
|
prevalence |
5 |
|
public health |
5 |
|
regression analysis |
5 |
|
remdesivir |
5 |
|
serial interval |
5 |
|
serial intervals |
5 |
|
staphylococcal infections - microbiology - prevention and control - transmission |
5 |
|
superspreading |
5 |
|
systematic review and meta-analysis |
5 |
|
temporal pattern |
5 |
|
virus shedding |
5 |
|
acute respiratory infections |
4 |
|
adrenal cortex hormones - therapeutic use |
4 |
|
anti-bacterial agents - pharmacology |
4 |
|
antiviral agents - therapeutic use |
4 |
|
back-projection method |
4 |
|
bacteremia - microbiology |
4 |
|
beijing sars |
4 |
|
canada - epidemiology |
4 |
|
cities - epidemiology |
4 |
|
cohort studies |
4 |
|
competing risk |
4 |
|
coronavirus |
4 |
|
correlation |
4 |
|
cost-effectiveness analysis |
4 |
|
counting process |
4 |
|
covid‐19 |
4 |
|
crf01-ae |
4 |
|
dna, bacterial - chemistry - genetics |
4 |
|
dpp4i |
4 |
|
drug administration schedule |
4 |
|
drug resistance, viral - genetics |
4 |
|
drug therapy, combination |
4 |
|
early diagnosis |
4 |
|
effectiveness |
4 |
|
epidemics |
4 |
|
female |
4 |
|
general population |
4 |
|
genes, gag |
4 |
|
genes, pol |
4 |
|
hazard of infection |
4 |
|
health benefit plans, employee - economics - statistics & numerical data |
4 |
|
health care workers |
4 |
|
health insurance |
4 |
|
health services |
4 |
|
health services needs and demand |
4 |
|
healthcare seeking behaviour |
4 |
|
hiv |
4 |
|
hiv infections - complications - epidemiology - virology |
4 |
|
hiv-1 - classification - drug effects - genetics |
4 |
|
hospitals |
4 |
|
hyperinflammatory syndrome |
4 |
|
immunity, duration |
4 |
|
imported cases |
4 |
|
in-hospital death |
4 |
|
incidence |
4 |
|
infection |
4 |
|
influenza a(h7n9) |
4 |
|
influenza activity |
4 |
|
influenza, human - microbiology - prevention and control |
4 |
|
influenza‐like illness |
4 |
|
information dissemination |
4 |
|
insurance, health - economics - statistics & numerical data |
4 |
|
internet |
4 |
|
kinetics |
4 |
|
l-lactate dehydrogenase |
4 |
|
male |
4 |
|
methicillin-resistant staphylococcus aureus |
4 |
|
methicillin-resistant staphylococcus aureus - drug effects - isolation & purification |
4 |
|
microbial sensitivity tests |
4 |
|
monitoring |
4 |
|
moral hazard |
4 |
|
morals |
4 |
|
mortality |
4 |
|
multilocus sequence typing |
4 |
|
mutation |
4 |
|
neutralizing antibody |
4 |
|
obesity |
4 |
|
online systems |
4 |
|
pandemics |
4 |
|
pattern |
4 |
|
phylogeny |
4 |
|
polymerase chain reaction |
4 |
|
predict |
4 |
|
pregnancy |
4 |
|
pregnancy complications, infectious - epidemiology |
4 |
|
propensity score |
4 |
|
protection |
4 |
|
recombination, genetic |
4 |
|
reproductive number |
4 |
|
respiratory distress syndrome, adult - drug therapy - mortality |
4 |
|
respiratory mortality |
4 |
|
retrospective studies |
4 |
|
ribavirin |
4 |
|
ribavirin - therapeutic use |
4 |
|
risk assessment |
4 |
|
school absenteeism |
4 |
|
school attendance |
4 |
|
sequence analysis, dna |
4 |
|
severe acute respiratory syndrome (sars) |
4 |
|
severe acute respiratory syndrome coronavirus 2 |
4 |
|
severity of illness index |
4 |
|
sex |
4 |
|
sexual transmission |
4 |
|
sickness absence |
4 |
|
social welfare - economics - statistics & numerical data |
4 |
|
staphylococcal infections - microbiology |
4 |
|
super-spreading event |
4 |
|
surveillance tolls |
4 |
|
symptom-specific |
4 |
|
systematic reviews |
4 |
|
time-varying fatality rate |
4 |
|
trend |
4 |
|
tuberculosis - epidemiology - transmission |
4 |
|
underlying risk factors |
4 |
|
vancomycin |
4 |
|
vancomycin - pharmacology |
4 |
|
vancomycin resistance |
4 |
|
viral clearance |
4 |
|
years of life lost |
4 |
|
young adult |
4 |
|
acute kidney injury |
3 |
|
adverse weather |
3 |
|
animal |
3 |
|
animal tissue |
3 |
|
antibiotic |
3 |
|
antiviral activity |
3 |
|
avian influenza virus |
3 |
|
awareness |
3 |
|
bayesian inference |
3 |
|
biometry - methods |
3 |
|
biostatistics |
3 |
|
blood donation |
3 |
|
blood inventory |
3 |
|
brownian motion |
3 |
|
central slaughtering |
3 |
|
clinical improvement |
3 |
|
co-infection |
3 |
|
correlation analysis |
3 |
|
cost |
3 |
|
cost analysis |
3 |
|
cost effectiveness |
3 |
|
counting |
3 |
|
crowd estimation |
3 |
|
disease duration |
3 |
|
disease outbreaks - statistics & numerical data |
3 |
|
donor |
3 |
|
environmental monitoring - statistics & numerical data |
3 |
|
epidemic |
3 |
|
epidemiological model |
3 |
|
ev-a71 infection |
3 |
|
experiment |
3 |
|
fatality rate |
3 |
|
flow model |
3 |
|
france |
3 |
|
h9n2 |
3 |
|
hospitalisation |
3 |
|
hospitalization - statistics & numerical data |
3 |
|
human |
3 |
|
human infection |
3 |
|
infection-fatality risk |
3 |
|
infectious disease |
3 |
|
influenza a (h7n9) |
3 |
|
influenza a virus, h1n1 subtype - isolation & purification |
3 |
|
influenza, human - epidemiology |
3 |
|
influenza, human - epidemiology - transmission - virology |
3 |
|
korea |
3 |
|
letter |
3 |
|
mathematical model |
3 |
|
methamphetamine |
3 |
|
models, statistical |
3 |
|
multinomial model |
3 |
|
neutralizing antibody level |
3 |
|
poisoning |
3 |
|
population surveillance |
3 |
|
poultry |
3 |
|
prospective studies |
3 |
|
public health service |
3 |
|
real-time fatality rate |
3 |
|
reassortment |
3 |
|
respiratory infection |
3 |
|
respiratory virus |
3 |
|
rest days |
3 |
|
school |
3 |
|
school closures |
3 |
|
school health service |
3 |
|
severe acute respiratory syndrome - mortality |
3 |
|
severity profile |
3 |
|
social distance |
3 |
|
social distancing measure |
3 |
|
stewardship |
3 |
|
substance-induced psychosis |
3 |
|
translation to population health |
3 |
|
transmission chain |
3 |
|
vaccine |
3 |
|
vaccine booster |
3 |
|
world health organization |
3 |
|
zero-mean martingale |
3 |
|
algorithms |
2 |
|
allergology and immunology medical sciences |
2 |
|
antigenicity |
2 |
|
basic reproductive number |
2 |
|
cardiovascular diseases |
2 |
|
clinical prognosis |
2 |
|
cost-effectiveness |
2 |
|
covid19 |
2 |
|
cross-sectional study |
2 |
|
epidemic model |
2 |
|
epilepsy |
2 |
|
febrile seizures |
2 |
|
kernel-smoothing method |
2 |
|
markov model |
2 |
|
martingale estimating equations |
2 |
|
medical help seek-behaviour |
2 |
|
naturally immune |
2 |
|
reliability and validity |
2 |
|
respiratory tract infections |
2 |
|
severe lupus nephritis |
2 |
|
susceptible |
2 |
|
therapeutic strategies |
2 |
|
triage |
2 |
|
anti-gq1b antibody syndrome |
1 |
|
bone mineral density |
1 |
|
disease progression |
1 |
|
guillain-barré syndrome |
1 |
|
health care–seeking behaviors |
1 |
|
logistic regression |
1 |
|
medications |
1 |
|
neuropathy |
1 |
|
osteopenia |
1 |
|
osteoporosis |
1 |
|
poultry supply chain |
1 |
|
poultry worker |
1 |
|
rheumatic diseases |
1 |
|
systemic lupus erythematosus |
1 |
|
transmission risk |
1 |
